Logo

Gilead and Galapagos NV's Filgotinib (JAK1i) Achieves Primary Endpoints for P-II TORTUGA study in AS patients

Share this

Gilead and Galapagos NV's Filgotinib (JAK1i) Achieves Primary Endpoints for P-II TORTUGA study in AS patients

Shots:

  • The P-II TORTUGA study is assessing safety and efficacy in moderate to severe ankylosing spondylitis (AS) adults in ratio of 1:1 administering filgotinib 200 mg or PBO qw for 12 wks.
  • TORTUGA results (N=116): improvement in AS disease- ASAS20 response (76% vs 40%)- ASDAS (-1.5 vs -0.6) with no new safety signals and deaths observed in study
  • TORTUGA study was conducted in Belgium- Bulgaria- Czech Republic- Estonia- Poland- Spain and Ukraine. Additionally- Filgotinib is being assessed in RA (FINCH P-III)- CD (SELECTION P-III) UC

   Ref: Gilead | Image: Gilead 

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions